A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Exclusion Criteria

• •History of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's assessment).
• •Previous or concomitant malignancies other than the one treated in this trial within the last 3 years except:
• •* Effectively treated non-melanoma skin cancers
• •* Effectively treated carcinoma in situ of the cervix
• •* Effectively treated ductal carcinoma in situ
• •* Other effectively treated malignancy that is considered cured by local treatment
• •Known leptomeningeal disease or spinal cord compression due to disease.
• •Require anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the Investigator.
• •Hepatitis C virus (HCV) infection, defined as:
• •* Currently receiving curative antiviral treatment for HCV infection, and/or
• •* HCV viral load is above the limit of quantification (HCV Ribonucleic acid (RNA) positive)
• •Hepatitis B virus (HBV) infection with the following laboratory evidence: positive results of hepatitis B surface (HBs) antigen and presence of Hepatitis B core (HBc) antibody together with HBV-deoxyribonucleic acid (DNA).
• •Patients with known history of human immunodeficiency virus (HIV) infection who meet one or more of the following criteria:
• •* Cluster of differentiation 4 (CD4+) count \<350 cells/μL (local lab assessment)
• •* Viral load \>400 copies/mL (local lab assessment)
• •* Not receiving antiretroviral therapy
• •* Receiving established antiretroviral therapy for less than four weeks prior to the start of study treatment
• •* History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months prior to start of study treatment Patients with a history of HIV who do not meet any of the criteria above are eligible to participate, but the patient must be under the care of a HIV/Infectious Diseases specialist, or a HIV/Infectious Diseases specialist must be consulted prior to inclusion.